ECSP15035343A - Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa pim - Google Patents

Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa pim

Info

Publication number
ECSP15035343A
ECSP15035343A ECIEPI201535343A ECPI201535343A ECSP15035343A EC SP15035343 A ECSP15035343 A EC SP15035343A EC IEPI201535343 A ECIEPI201535343 A EC IEPI201535343A EC PI201535343 A ECPI201535343 A EC PI201535343A EC SP15035343 A ECSP15035343 A EC SP15035343A
Authority
EC
Ecuador
Prior art keywords
pim kinase
bond
thiazolcarboxamides
pyridinacarboxamide
kinase inhibitors
Prior art date
Application number
ECIEPI201535343A
Other languages
English (en)
Inventor
Anlai Wang
Chu-Biao Xue
Yun-Long Li
Jioncong Zhuo
Ke Zhang
Hao Feng
Wenqing Yao
Fenglei Zhang
Jun Pan
Original Assignee
Howe Arlene R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Howe Arlene R filed Critical Howe Arlene R
Publication of ECSP15035343A publication Critical patent/ECSP15035343A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción describe derivados de carboxamida de tiazol y piridina de la fórmula (I), o su sal farmacéuticamente aceptable, en donde: X es C o N; A, B y D son anillos; el enlace – representa un enlace normalizado en donde el anillo aromático que contiene ambos, un N y X, que están representados formalmente por un enlace C=C cuando X es C y un enlace simple cuando X es N; el anillo A es de la fórmula (A-1) o (A-2): donde E1 y E2 son anillos; sus composiciones y métodos de uso. Los compuestos inhiben la actividad de las quinasas Pim y son útiles en el tratamiento de enfermedades relacionadas con la actividad de las quinasas Pim incluyendo, por ejemplo, cáncer y otras enfermedades.
ECIEPI201535343A 2013-01-15 2015-08-14 Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa pim ECSP15035343A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752897P 2013-01-15 2013-01-15
US201361790952P 2013-03-15 2013-03-15
US201361859118P 2013-07-26 2013-07-26

Publications (1)

Publication Number Publication Date
ECSP15035343A true ECSP15035343A (es) 2017-03-31

Family

ID=50031607

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201535343A ECSP15035343A (es) 2013-01-15 2015-08-14 Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa pim

Country Status (35)

Country Link
US (7) US9200004B2 (es)
EP (3) EP2945939B1 (es)
JP (3) JP6554037B2 (es)
KR (2) KR102403306B1 (es)
CN (2) CN105051029B (es)
AR (1) AR094664A1 (es)
AU (3) AU2014207691B2 (es)
BR (2) BR112015016793B1 (es)
CA (1) CA2897333C (es)
CL (1) CL2015001985A1 (es)
CR (1) CR20150412A (es)
CY (1) CY1122933T1 (es)
DK (1) DK2945939T3 (es)
EA (1) EA035929B1 (es)
EC (1) ECSP15035343A (es)
ES (2) ES2941292T3 (es)
HK (1) HK1216424A1 (es)
HR (1) HRP20200770T1 (es)
HU (1) HUE050215T2 (es)
IL (1) IL239886B (es)
LT (1) LT2945939T (es)
ME (1) ME03780B (es)
MX (2) MX2020011085A (es)
NZ (2) NZ749911A (es)
PE (2) PE20151448A1 (es)
PH (2) PH12015501567B1 (es)
PL (1) PL2945939T3 (es)
PT (1) PT2945939T (es)
RS (1) RS60244B1 (es)
SG (3) SG11201505347VA (es)
SI (1) SI2945939T1 (es)
TW (2) TW201932456A (es)
UA (1) UA121098C2 (es)
WO (1) WO2014113388A1 (es)
ZA (1) ZA202108141B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
TW201932456A (zh) 2013-01-15 2019-08-16 美商英塞特控股公司 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
MA40875B1 (fr) * 2014-10-31 2019-01-31 Genoscience Pharma Sas 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
CN104876929B (zh) * 2015-05-15 2016-10-05 华南理工大学 一种1,2,3,4-四氢萘啶类化合物的合成方法及应用
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) * 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
LT3377488T (lt) 2015-11-19 2023-01-10 Incyte Corporation Heterocikliniai junginiai, kaip imunomoduliatoriai
BR112018012756A2 (pt) 2015-12-22 2018-12-04 Incyte Corp compostos heterocíclicos como imunomoduladores
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
SI3472167T1 (sl) 2016-06-20 2022-11-30 Incyte Corporation Heterociklične spojine kot imunomodulatorji
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
CN106336371A (zh) * 2016-08-16 2017-01-18 成都百事兴科技实业有限公司 叔丁氧羰基‑l‑焦谷氨酸甲酯的合成方法
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
CN110267953B (zh) 2016-12-22 2022-12-20 因赛特公司 四氢咪唑并[4,5-c]吡啶衍生物作为pd-l1内在化诱导剂
WO2018177993A1 (de) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Pyrazole zur bekämpfung von arthropoden
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
MX2020009228A (es) 2018-03-08 2021-01-08 Incyte Corp Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma.
HRP20230090T1 (hr) 2018-03-30 2023-03-17 Incyte Corporation Heterociklički spojevi kao imunomodulatori
EP3773560A4 (en) 2018-04-13 2022-01-19 Sumitomo Dainippon Pharma Oncology, Inc. PIM KINASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND CANCER-ASSOCIATED FIBROSIS
CN112752756B (zh) 2018-05-11 2024-06-25 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020097577A1 (en) * 2018-11-09 2020-05-14 Prelude Therapeutics, Incorporated Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
CN113412262A (zh) 2019-02-12 2021-09-17 大日本住友制药肿瘤公司 包含杂环蛋白激酶抑制剂的制剂
WO2020221334A1 (en) * 2019-04-30 2020-11-05 City University Of Hong Kong Pim1 inhibitors for use in treatment of viral infection and pharmaceutical compositions thereof
MX2021015996A (es) 2019-07-11 2022-06-08 Escape Bio Inc Indazoles y azaindazoles como inhibidores de cinasa de repetición rica en leucina 2 (lrrk2).
AR119624A1 (es) 2019-08-09 2021-12-29 Incyte Corp Sales de un inhibidor de pd-1 / pd-l1
MX2022003578A (es) 2019-09-30 2022-05-30 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores.
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
PE20231438A1 (es) 2020-11-06 2023-09-14 Incyte Corp Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
WO2023170024A1 (en) * 2022-03-11 2023-09-14 University Of Copenhagen Camk2 modulators and their use in medicine
WO2024097653A1 (en) 2022-10-31 2024-05-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2413330A1 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
WO2002055489A2 (en) 2000-12-27 2002-07-18 Univ Columbia Pim kinase-related methods
DE10123055A1 (de) 2001-05-11 2003-03-20 Gruenenthal Gmbh Screeningverfahren mit PIM1-Kinase oder PIM3-Kinase
DE10226702A1 (de) 2002-06-14 2004-09-09 Grünenthal GmbH Antisense Oligonukleotide gegen PIM1
WO2006078228A1 (en) 2002-09-16 2006-07-27 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
EP1558751A4 (en) 2002-09-16 2007-08-22 Plexxikon Inc CRYSTALLINE STRUCTURE OF PROTEIN KINASE PIM-1
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
WO2004090106A2 (en) 2003-04-04 2004-10-21 Vertex Pharmaceuticals Incorporated Crystal structures of human pim-1 kinase protein complexes and binding pockets thereof, and uses thereof in drug design
WO2005028624A2 (en) 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
WO2005033310A1 (de) 2003-10-01 2005-04-14 Grünenthal GmbH Pim-1-spezifische dsrna-verbindungen
WO2006006569A1 (ja) 2004-07-12 2006-01-19 Nihon Nohyaku Co., Ltd. フェニルピリジン類又はその塩類、これらを有効成分とする除草剤及びその使用方法
PL1836169T3 (pl) 2004-12-28 2012-07-31 Kinex Pharmaceuticals Llc Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
CA2613015C (en) 2005-06-22 2012-04-03 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
AR056206A1 (es) 2005-10-06 2007-09-26 Schering Corp Pirazolpirimidinas como inhibidores de protein quinasas
US8053454B2 (en) 2005-10-06 2011-11-08 Exelixis, Inc. Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3
CA2626789A1 (en) 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
US20090182003A1 (en) 2006-01-13 2009-07-16 President And Fellows Of Harvard College Methods and Compositions for Treatment Cell Proliferative Disorders
US20090253156A1 (en) 2006-05-05 2009-10-08 Perkinelmer Las, Inc. Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases
PT2041071E (pt) 2006-06-29 2014-09-23 Kinex Pharmaceuticals Llc Composições de biarilo e processos para a regulação de uma cascata de cinases
AU2007265373B2 (en) 2006-06-29 2013-02-21 Atnx Spv, Llc Biaryl compositions and methods for modulating a kinase cascade
JP5252404B2 (ja) 2006-08-16 2013-07-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラジン化合物、その使用及び調製方法
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
AR063531A1 (es) 2006-10-31 2009-01-28 Schering Corp Derivados de anilinopiperazina y composicion farmaceutica
MY146474A (en) 2006-11-06 2012-08-15 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008082840A1 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
EP2132177B1 (en) 2007-03-01 2013-07-17 Novartis AG Pim kinase inhibitors and methods of their use
CN101679422A (zh) 2007-03-28 2010-03-24 阵列生物制药公司 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物
US8138181B2 (en) 2007-04-03 2012-03-20 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
AU2008244490B2 (en) 2007-04-25 2014-02-27 Exelixis, Inc. 6-phenylpyrimidinones as PIM modulators
KR20100017359A (ko) 2007-04-25 2010-02-16 엑셀리시스, 인코포레이티드 카제인 키나제 ⅱ （ｃｋ２）조절제로서의 피리미디논
CA2693967A1 (en) 2007-07-19 2009-01-29 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
US20100249030A1 (en) * 2007-07-31 2010-09-30 Schering Corporation Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
ES2534899T3 (es) 2007-08-06 2015-04-30 Janssen Pharmaceutica, N.V. Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53
WO2009064486A2 (en) 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
EP2209889B1 (en) 2007-11-16 2016-07-20 San Diego State University Research Foundation Compositions for manipulating pim-1 activity in cardiac cells
AU2009219154A1 (en) 2008-02-29 2009-09-03 Cylene Pharmaceuticals, Inc. Protein kinase modulators
AR070531A1 (es) * 2008-03-03 2010-04-14 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
US8168794B2 (en) * 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
AU2009246568A1 (en) 2008-05-12 2009-11-19 Amnestix, Inc. Compounds for improving learning and memory
CN102137866A (zh) 2008-06-30 2011-07-27 赛林药物股份有限公司 羟吲哚化合物
TWI461423B (zh) 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
FR2933409B1 (fr) 2008-07-03 2010-08-27 Centre Nat Rech Scient NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
US8557809B2 (en) 2008-08-19 2013-10-15 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
JP5584215B2 (ja) 2008-09-02 2014-09-03 ノバルティス アーゲー ヘテロ環ｐｉｍキナーゼ阻害剤
CN103333157A (zh) 2008-09-02 2013-10-02 诺瓦提斯公司 作为激酶抑制剂的吡啶甲酰胺衍生物
WO2010026121A1 (en) 2008-09-02 2010-03-11 Novartis Ag Bicyclic kinase inhibitors
KR102037619B1 (ko) 2008-10-22 2019-10-28 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
EP2376491B1 (en) 2008-12-19 2015-03-04 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
ES2552805T3 (es) 2009-04-20 2015-12-02 Auspex Pharmaceuticals, Llc Inhibidores piperidínicos de la cinasa Janus 3
US20120128631A1 (en) 2009-05-19 2012-05-24 San Diego State University (SDSU) Foundation, dba San Diego State University (SDSU) Research Compositions and methods for kinase-mediated cytoprotection and enhanced cellular engraftment and persistence
WO2010135571A1 (en) 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Novel protein kinase modulators
MX2011012369A (es) 2009-05-20 2012-03-16 Cylene Pharmaceuticals Inc Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.
MX2011012353A (es) 2009-05-22 2011-12-14 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
US20100331315A1 (en) 2009-06-18 2010-12-30 Mustapha Haddach Rhodanines and related heterocycles as kinase inhibitors
ES2486715T3 (es) 2009-06-29 2014-08-19 Incyte Corporation Pirimidinonas como inhibidores de PI3K
SG178552A1 (en) 2009-08-26 2012-03-29 Cylene Pharmaceuticals Inc Condensed quinolines as protein kinase modulators
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
JP5567136B2 (ja) * 2009-09-08 2014-08-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ４−置換ピリジン−３−イル−カルボキサミド化合物及び使用方法
US8435976B2 (en) 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
WO2011031979A1 (en) 2009-09-11 2011-03-17 Cylene Pharmaceuticals Inc. Pharmaceutically useful heterocycle-substituted lactams
BR112012005970A2 (pt) 2009-09-16 2015-09-08 Cylene Pharmaceuticals Inc moduladores tricíclicos de proteína quinase
BR112012005957A2 (pt) 2009-09-16 2019-09-24 Cylene Pharmaceuticals Inc compostos tricíclicos e usos farmacêuticos dos mesmos
MY173494A (en) 2009-10-29 2020-01-29 Genosco Kinase inhibitors
EP2332917B1 (en) 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Compounds for PIM kinase inhibition and for treating malignancy
JP2013510824A (ja) 2009-11-12 2013-03-28 セルビタ エス．エー． セリン／トレオニンキナーゼを調節または制御するための化合物、その調製のための方法、医薬組成物、化合物の使用、方法ならびにセリン／トレオニンキナーゼ調節剤
EP2498607B1 (en) 2009-11-13 2016-02-17 Genosco Kinase inhibitors
US8853235B2 (en) 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
PL2509602T3 (pl) 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
TW201130842A (en) 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011075613A1 (en) 2009-12-18 2011-06-23 Sanofi Azaindole derivatives, their preparation and their therapeutic application
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011079274A1 (en) 2009-12-23 2011-06-30 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
GB201002861D0 (en) 2010-02-19 2010-04-07 Cxr Biosciences Ltd Compositions
AR081315A1 (es) 2010-03-10 2012-08-08 Incyte Corp Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t
KR101464060B1 (ko) 2010-04-07 2014-11-20 에프. 호프만-라 로슈 아게 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP2013530199A (ja) 2010-07-06 2013-07-25 ノバルティス アーゲー キナーゼ阻害剤として有用な環状エーテル化合物
WO2012007375A1 (en) 2010-07-13 2012-01-19 F. Hoffmann-La Roche Ag Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators
PT2598483T (pt) 2010-07-29 2020-10-12 Rigel Pharmaceuticals Inc Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos
US8227773B2 (en) 2010-07-29 2012-07-24 Axcelis Technologies, Inc. Versatile beam glitch detection system
EP2637650A2 (en) 2010-11-10 2013-09-18 National Jewish Health Methods to test allergic conditions
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
BR112013012502A2 (pt) 2010-11-19 2019-03-06 Incyte Corporation pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
EP2796456A1 (en) 2010-12-09 2014-10-29 Amgen Inc. Bicyclic compounds as Pim inhibitors
CN103298816A (zh) 2010-12-17 2013-09-11 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代的吡唑并-喹唑啉衍生物
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
JP5925809B2 (ja) 2011-01-26 2016-05-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用
US8916577B2 (en) 2011-01-26 2014-12-23 Nerviano Medical Sciences S.R.L. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
SI2678329T1 (sl) 2011-02-25 2016-05-31 Array Biopharma Inc. Triazolopiridinske spojine kot inhibitorji kinaze pim
UY33930A (es) * 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
US20120225061A1 (en) 2011-03-04 2012-09-06 Matthew Burger Tetrasubstituted cyclohexyl compounds as kinase inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
EP2688886A1 (en) 2011-03-22 2014-01-29 Amgen Inc. Azole compounds as pim inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
BR112013025792A2 (pt) 2011-04-05 2018-04-24 Pfizer Ltd Inibidores de quinase relacionada à pirrolo[2,3-d] pirimidina tropomisina
EP2702055A1 (en) 2011-04-11 2014-03-05 Nerviano Medical Sciences S.r.l. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
CA2832865C (en) 2011-04-22 2021-05-11 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
GB201107176D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Pyrrolnitrin derivatives
GB201107197D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Compounds
JP2014516941A (ja) 2011-04-29 2014-07-17 アムジェン インコーポレイテッド Ｐｉｍ阻害剤としての二環式ピリダジン化合物
WO2012156367A1 (en) 2011-05-17 2012-11-22 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
AU2012257513B2 (en) 2011-05-19 2017-05-11 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
RU2013157898A (ru) 2011-05-27 2015-07-10 Темпл Юниверсити-Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн ЗАМЕЩЕННЫЕ 2-БЕНЗИЛИДЕН-2H-БЕНЗО[b][1,4]ТИАЗИН-3(4H)-ОНЫ, ИХ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПЕВТИЧЕСКИХ ЦЕЛЯХ
ES2625854T3 (es) 2011-06-01 2017-07-20 Bayer Intellectual Property Gmbh Aminoimidazopiridazinas sustituidas
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
MX344479B (es) 2011-06-20 2016-12-16 Incyte Holdings Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de cinasa janus (jak).
US9284319B2 (en) 2011-06-22 2016-03-15 Bayer Intellectual Property Gmbh Heterocyclyl aminoimidazopyridazines
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
CN102924445B (zh) 2011-08-11 2015-07-08 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
MX355852B (es) 2011-08-12 2018-05-02 Hoffmann La Roche Compuestos de pirazolo [3,4-c] piridina y métodos de uso.
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
EP2751109B1 (en) 2011-09-02 2016-11-30 Incyte Holdings Corporation Heterocyclylamines as pi3k inhibitors
JP5843524B2 (ja) 2011-09-02 2016-01-13 キヤノン株式会社 有機無機複合組成物、有機無機複合材料、光学素子および積層型回折光学素子
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN103814029B (zh) 2011-09-23 2016-10-12 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
SG2014012579A (en) 2011-09-27 2014-04-28 Hoffmann La Roche Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
US9145418B2 (en) 2011-10-07 2015-09-29 Nerviano Medical Sciences S.R.L. Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
US9181258B2 (en) 2011-10-07 2015-11-10 Nerviano Medical Sciences S.R.L. Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
RU2674017C2 (ru) 2011-11-04 2018-12-04 ДЖАСКО ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Аминопиримидиновые ингибиторы киназ
US9394297B2 (en) 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
US9340549B2 (en) 2012-03-05 2016-05-17 Amgen Inc. Oxazolidinone compounds and derivatives thereof
CN104487440B (zh) 2012-03-29 2016-11-23 拜耳知识产权有限责任公司 氨基取代的咪唑并哒嗪
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
ES2660981T3 (es) 2012-04-04 2018-03-26 Bayer Pharma Aktiengesellschaft Imidazopiridazinas sustituidas con amino
UY34763A (es) 2012-04-26 2013-10-31 Bristol Myers Squibb Co Inhibidores de la agregación plaquetaria
WO2013160873A1 (en) 2012-04-27 2013-10-31 Novartis Ag Cyclic bridgehead ether dgat1 inhibitors
NZ702663A (en) 2012-05-09 2017-03-31 Karyopharm Therapeutics Inc Nuclear transport modulators and uses thereof
CU24265B1 (es) 2012-05-15 2017-07-04 Novartis Ag Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, útiles en el tratamiento del cáncer
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US9173883B2 (en) 2012-05-21 2015-11-03 Novartis Ag Ring-substituted N-pyridinyl amides as kinase inhibitors
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
KR20150028999A (ko) 2012-06-27 2015-03-17 에프. 호프만-라 로슈 아게 5-아자인다졸 화합물 및 이의 사용 방법
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
CN103664878A (zh) 2012-09-12 2014-03-26 山东亨利医药科技有限责任公司 杂芳环及其衍生物类酪氨酸激酶抑制剂
JP6290217B2 (ja) 2012-09-14 2018-03-07 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 三環式キノリンおよびキノキサリン誘導体
DK2900657T3 (da) 2012-09-26 2020-05-04 Hoffmann La Roche Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
WO2014053568A1 (en) 2012-10-02 2014-04-10 Sanofi Indolyldihydroimidazopyrimidinone derivatives, preparation thereof and therapeutic use thereof
MX363717B (es) 2012-10-16 2019-03-29 Janssen Sciences Ireland Uc Compuestos antiviricos para el virus sincitial respiratorio.
EA031882B1 (ru) 2012-11-01 2019-03-29 Инсайт Холдингс Корпорейшн Трициклические конденсированные производные тиофена как ингибиторы jak
JP2015537017A (ja) 2012-11-19 2015-12-24 バイエル ファーマ アクチエンゲゼルシャフト アミノイミダゾピリダジン類
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
TR201807740T4 (tr) 2012-12-07 2018-06-21 Vertex Pharma ATR kinaz inhibitörü olarak 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid.
RU2667060C2 (ru) 2012-12-18 2018-09-14 Вертекс Фармасьютикалз Инкорпорейтед Производные маннозы для лечения бактериальных инфекций
AU2013365742B2 (en) 2012-12-19 2016-11-24 Novartis Ag Autotaxin inhibitors
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
LT3067358T (lt) 2012-12-21 2019-11-25 Gilead Sciences Inc Policikliniai karbamoilpiridono junginiai ir jų farmacinis panaudojimas
KR102024417B1 (ko) 2012-12-21 2019-11-07 에피자임, 인코포레이티드 테트라하이드로- 및 디하이드로-이소퀴놀린 prmt5 억제제 및 이의 용도
FR3000569B1 (fr) 2013-01-03 2015-02-13 Peugeot Citroen Automobiles Sa Dispositif d'eclairage a ecran a bord(s) lumineux
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
TW201932456A (zh) 2013-01-15 2019-08-16 美商英塞特控股公司 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
TW202214254A (zh) 2013-03-01 2022-04-16 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
RS58547B1 (sr) 2013-03-06 2019-05-31 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
US20160052926A1 (en) 2013-03-15 2016-02-25 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
EP3805205A1 (en) 2013-03-15 2021-04-14 Japan Tobacco Inc. Pyrazole-amide compound and medicinal uses therefor
JP6243003B2 (ja) 2013-03-15 2017-12-06 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤としての三環式複素環
KR20150132146A (ko) 2013-03-15 2015-11-25 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
CN110583663A (zh) 2013-03-15 2019-12-20 美国陶氏益农公司 式(i)化合物及其作为除草剂的用途
SG11201506687RA (en) 2013-03-15 2015-09-29 Plexxikon Inc Heterocyclic compounds and uses thereof
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
US9617250B2 (en) 2013-03-15 2017-04-11 Actelion Pharmaceuticals Ltd. Pyridin-4-yl derivatives
TWI742541B (zh) 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
KR102293060B1 (ko) 2013-03-15 2021-08-23 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
UY35421A (es) 2013-03-15 2014-10-31 Nihon Nohyaku Co Ltd Compuesto heterocíclico condensado o su sal, insecticida agrícola u hortícola que comprende el comp uesto y método de uso del insecticida
MY195091A (en) 2013-08-07 2023-01-10 Incyte Corp Sustained Release Dosage Forms for a JAK1 Inhibitor
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
SI3110409T1 (sl) 2014-02-28 2018-11-30 Incyte Corporation Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov
MX2020004398A (es) 2014-04-08 2022-06-06 Incyte Corp Tratamiento de neoplasias malignas de linfocitos b mediante una combinacion de inhibidores de janus cinasa (jak) y fosfatidilinositol 3 cinasa (pi3k).
US9802957B2 (en) 2014-04-30 2017-10-31 Incyte Corporation Processes of preparing a JAK1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors

Also Published As

Publication number Publication date
US10828290B2 (en) 2020-11-10
AR094664A1 (es) 2015-08-19
US10517858B2 (en) 2019-12-31
PE20151448A1 (es) 2015-09-28
ME03780B (me) 2021-04-20
HRP20200770T1 (hr) 2020-07-24
WO2014113388A1 (en) 2014-07-24
JP6775645B2 (ja) 2020-10-28
IL239886B (en) 2021-03-25
US11229631B2 (en) 2022-01-25
ES2941292T3 (es) 2023-05-19
US20190209537A1 (en) 2019-07-11
AU2018217210C1 (en) 2020-08-27
PE20191245A1 (es) 2019-09-18
KR102403306B1 (ko) 2022-06-02
AU2020201114A1 (en) 2020-03-05
CN105051029A (zh) 2015-11-11
PH12015501567A1 (en) 2015-09-21
EP2945939A1 (en) 2015-11-25
US20200405702A1 (en) 2020-12-31
MX2015009057A (es) 2015-10-05
AU2014207691B2 (en) 2018-08-30
CN108715590A (zh) 2018-10-30
EA201591339A1 (ru) 2015-12-30
AU2014207691A1 (en) 2015-08-06
CN105051029B (zh) 2018-07-31
RS60244B1 (sr) 2020-06-30
JP2019206539A (ja) 2019-12-05
SI2945939T1 (sl) 2020-08-31
MX2020011085A (es) 2022-07-20
BR112015016793A2 (pt) 2017-07-11
US9550765B2 (en) 2017-01-24
HK1216424A1 (zh) 2016-11-11
NZ749911A (en) 2020-02-28
JP6554037B2 (ja) 2019-07-31
US10265307B2 (en) 2019-04-23
BR122019024759B1 (pt) 2022-02-08
BR112015016793B1 (pt) 2021-12-28
AU2020201114B2 (en) 2021-03-25
SG10201912524QA (en) 2020-04-29
TWI662030B (zh) 2019-06-11
HUE050215T2 (hu) 2020-11-30
NZ710079A (en) 2020-01-31
EP3670506B1 (en) 2023-01-04
PT2945939T (pt) 2020-06-08
CA2897333A1 (en) 2014-07-24
EA035929B1 (ru) 2020-09-02
CN108715590B (zh) 2022-03-08
SG10201705662WA (en) 2017-08-30
JP6987937B2 (ja) 2022-01-05
KR20150113019A (ko) 2015-10-07
EP4186897A1 (en) 2023-05-31
US20170182017A1 (en) 2017-06-29
US20140200227A1 (en) 2014-07-17
KR102311840B1 (ko) 2021-10-14
EP2945939B1 (en) 2020-03-04
SG11201505347VA (en) 2015-08-28
JP2016505020A (ja) 2016-02-18
JP2020200338A (ja) 2020-12-17
CY1122933T1 (el) 2021-10-29
US20200155527A1 (en) 2020-05-21
US9200004B2 (en) 2015-12-01
EP3670506A1 (en) 2020-06-24
DK2945939T3 (da) 2020-03-23
ZA202108141B (en) 2023-06-28
KR20210110754A (ko) 2021-09-08
AU2018217210B2 (en) 2020-02-20
US9849120B2 (en) 2017-12-26
TW201444823A (zh) 2014-12-01
UA121098C2 (uk) 2020-04-10
PL2945939T3 (pl) 2020-08-24
TW201932456A (zh) 2019-08-16
US20180193323A1 (en) 2018-07-12
LT2945939T (lt) 2020-07-27
IL239886A0 (en) 2015-08-31
PH12020500485A1 (en) 2021-06-14
CL2015001985A1 (es) 2015-10-02
CA2897333C (en) 2021-07-06
AU2018217210A1 (en) 2018-08-30
PH12015501567B1 (en) 2015-09-21
ES2790419T3 (es) 2020-10-27
US20150329534A1 (en) 2015-11-19
CR20150412A (es) 2015-10-27

Similar Documents

Publication Publication Date Title
ECSP15035343A (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa pim
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CO2017011851A2 (es) Compuestos novedosos
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CU20160087A7 (es) Indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen
CO2017012566A2 (es) Piridinas sustituidas y método de uso
CL2015002520A1 (es) Compuestos novedosos de pirimidina y piridina y su uso.
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
DOP2017000034A (es) Compuestos de imidazopiridazina
CO2017012994A2 (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
DOP2017000244A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
CL2018003158A1 (es) Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3.
EA202090672A3 (ru) Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
BR112017021114A8 (pt) Compostos heterocíclicos como inibidores de lsd1
TH1501004024A (th) สารกลุ่มไธอะโซลคาร์บอกซาไมด์และสารประกอบไพริดีนคาร์บอกซาไมด์ที่เป็น ประโยชน์สำหรับใช้เป็นสารยับยั้บ pim ไคเนส